Head and Neck Cancer: Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation
in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)
What is the safety, tolerability and anti-tumor activity of the research study drug
pembrolizumab (MK-3475) in combination with chemoradiation (CRT) to placebo in combination
with CRT in subjects with locally advanced head and neck squamous cell carcinoma?
Basic Study Information
Purpose:Location: Cancer Center
You will be assigned to one of two possible study drug treatments: pembrolizumab or
placebo in addition to chemoradiation. you have a 1 in 2 chance of getting placebo,
neither you or your study doctor will know which of these you are receiving.
Study Web URL: https://clinicaltrials.gov/ct2/show/NCT03040999?term=3475-412&rank=1
Study Reference #: IHAN17023
Lead Researcher (Principal Investigator)
Lead Researcher: Ronald Maggiore
Study Contact InformationStudy Coordinator: Park Bogan
Phone: (585) 276-4415
Additional Study Details
Learn More About These Conditions
More information about Carcinoma, Squamous Cell
Trial Not Found
The study you are looking for is not active at this time.
Return to Search